FALSE000159678300015967832022-09-092022-09-09


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________ 
FORM 8-K
CURRENT REPORT
______________________________ 
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 9, 2022
CATALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36587
20-8737688
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
14 Schoolhouse Road
Somerset, New Jersey08873
(Address of registrant's principal executive office)(Zip code)
(732) 537-6200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbols(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
CTLT
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
        
Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 




Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

New Chief Accounting Officer

On September 9, 2022, the board of directors of Catalent, Inc. (“Catalent” and, together with its subsidiaries, the “Company”), acting by unanimous written consent, elected Karen Santiago Vice President and Chief Accounting Officer (“CAO”), effective as of the commencement of her employment with the Company, which occurred on September 19, 2022 (the “Effective Date”). She will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.

Prior to joining Catalent, Ms. Santiago spent 19 years with Bristol-Myers Squibb Company in various roles of increasing responsibility, including Senior Vice President & Corporate Controller, Principal Accounting Officer from 2018 to 2022 and Lead Enabling Functions and Finance Transformation from 2016 to 2018. Since 2013 she has served on the board of The Arc of New Jersey, the state's largest organization advocating for and serving children and adults with intellectual and developmental disabilities and their families. She holds a Masters in Business Administration and a Bachelor of Science in Accounting from Rutgers University.

There is no arrangement or understanding between Ms. Santiago and any other person pursuant to which she was selected as CAO. There is also no family relationship between Ms. Santiago and any director or executive officer of Catalent, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company has entered into an offer letter, dated August 29, 2022, with Ms. Santiago (the “Offer Letter”), as well as a severance agreement which provides for terms applicable to all senior executives other than Catalent’s Chief Executive Officer and is substantially in the form (the “Form Severance Agreement”) provided as Exhibit 10.3 to the Annual Report on Form 10-K filed September 17, 2010 by Catalent’s wholly owned subsidiary, Catalent Pharma Solutions, Inc. The terms of the Offer Letter and the Form Severance Agreement are summarized as follows:

Base Salary. Ms. Santiago’s annual base salary will $360,000.

Bonus. Ms. Santiago will be eligible for a cash bonus under the terms of the Company’s Management Incentive Plan, or MIP, the incentive-based annual cash bonus plan for the Company’s executives, with a target amount of $260,000.

Long-Term Incentive Award. Ms. Santiago will be eligible to participate in Catalent’s Long-Term Incentive Plan (the “LTIP”), with an annual grant target of $330,000 beginning with a pro rata grant in respect of Catalent’s 2023 fiscal year, allocated in the same manner as applies to all members of the Company’s Executive Leadership Team, with 30% granted as stock options, 20% as restricted stock units (“RSUs”), and 50% as performance-based RSUs (also known as “performance share units”) under Catalent’s 2018 Omnibus Incentive Plan (the “2018 Omnibus Plan”) provided as Exhibit 10.1 to Catalent’s Quarterly Report on Form 10-Q filed November 6, 2018.

Termination of Employment. Under her severance agreement, if Ms. Santiago were involuntarily terminated for any reason (including by her for “Good Reason,” as defined in that agreement) other than “Cause” (as defined in that agreement), death or disability, she would be entitled to (i) a severance payment equal to the sum of annual base salary and target annual bonus, payable in equal installments over the one-year period following the date of termination; and (ii) continued participation for up to one year in the Company’s group health plans (to the extent she was receiving such coverage as of the termination date), at the same premium rates as may be charged from time to time to the Company’s U.S. employees generally. In addition, under the LTIP, a termination without cause within 18 months of a change in control would result in Ms. Santiago’s unvested awards becoming fully vested and exercisable.

The foregoing descriptions of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the Form Severance Agreement are qualified in their entirety by reference to the Offer Letter and the Form Severance Agreement, with the full text of each item incorporated herein by reference.
2



In addition to providing the Offer Letter, Catalent agreed to grant to Ms. Santiago, as of the Effective Date, RSUs under the 2018 Omnibus Plan with a grant-date value of $150,000, which RSUs will vest on the third anniversary of grant, subject to her continued employment with the Company and her execution of and compliance with an award agreement substantially in the form provided as Exhibit 10.40 to Catalent’s Quarterly Report on Form 10-Q filed May 7, 2019, the full text of which is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On September 19, 2022, the Company issued a press release announcing Catalent’s election of Karen Santiago as Vice President and CAO. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

d. Exhibits. The following exhibits are filed (or, in the case of Exhibit 99.1, furnished) as part of this Current Report on Form 8-K.
Exhibit No.Description
Offer letter, dated August 29, 2022, between Karen Santiago and the Company
Press release, dated September 19, 2022, issued by the Company
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Catalent, Inc.
(Registrant)
By:/s/ STEVEN L. FASMAN
Steven L. Fasman
Executive Vice President, Chief Administrative Officer


Date: September 19, 2022
3



imagea.jpg

August 29, 2022

Karen Santiago
[Address on file with Company]


Dear Karen:

Congratulations on your offer to join our growing team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s expertise and capabilities and its collaborations with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help us develop, supply, and deliver billions of doses of life-enhancing products. We take great pride in hiring professionals like you, who have talent, drive, and commitment. We can’t wait to have you join us as we work to advance new medicines for the benefit of patients around the world. We’re confident that you will find your career with Catalent to be filled with opportunities, new challenges, and meaningful work. Attached is important information about our organization and your individual position, rewards, and benefits.

The major provisions of your offer, which is subject to the approval of the Board of Directors or its Compensation and Leadership Committee (CLC), are:

Position: Your position will be Vice President and Chief Accounting Officer, based in our Somerset, NJ corporate headquarters and reporting directly to Thomas Castellano, SVP & CFO. You will also be a member of Catalent’s Executive Leadership Team (ELT).

Compensation: Your bi-weekly base rate of pay will be $13,847 (annualized to $360,000). Catalent employees are paid every other Friday, one week in arrears (one week behind the most current workweek you’ve completed).

Performance: Performance and merit-based compensation are reviewed as part of an annual process that generally takes place during the first quarter of each fiscal year.

Rewards: Catalent is pleased to offer a comprehensive, competitive compensation program that rewards talented employees for their performance. Effective on your first day of employment, you will be eligible for our health, life, disability, and 401(k) retirement savings plans. You will receive more information on these benefits during your new hire orientation session.

You are eligible to participate in Catalent’s short-term incentive plan, which we call the Management Incentive Plan (MIP). Your annual incentive target will be $260,000. You will be eligible for a MIP bonus beginning in our 2023 fiscal year (July 1, 2022 – June 30, 2023), pro- rated based on your hire date. Annual bonus payments are determined based upon the achievement of specific company and personal objectives and are not guaranteed. In order to receive your MIP payment, you must be actively employed at the time of payout. Please refer to the MIP Summary document for further details.

In recognition of your leadership position, you will be recommended to receive a Long-Term Incentive Plan (LTIP) grant equal to $330,000. Since LTIP grants have equity components, your grant is subject to the approval of the CLC. The grant date will be your hire date. In future years, LTIP grants are made during the first quarter of each fiscal year in accordance with Catalent’s standard equity grant cycle. The complete terms and conditions of the LTIP, including the equity components and related award agreements, will be provided to you shortly after your hire date and are conditioned on, among other things, your acceptance of certain restrictive covenants.




Subject to the approval of the CLC, you will receive a special Restricted Stock Unit (RSU) grant with a grant value of $150,000. The RSUs will cliff vest on the third anniversary of your hire date.

You will be eligible to participate in Catalent’s Deferred Compensation Plan, which enables you to save over the IRS limits in the qualified 401(k) plan. Complete details on the features of this plan and how to enroll will be mailed to your home following your hire date.

Paid Time Off: Upon joining Catalent you will receive eight (8) paid company holidays (New Year’s Day, MLK Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and the day following, and Christmas Day).

You will be eligible to receive 208 hours (26 days) of PTO per calendar year, pro-rated based on the number of months you are employed during your first calendar year. Future increases to PTO entitlement will be in accordance with Catalent’s prevailing Company PTO policy. PTO includes vacation, sick, and personal days. Catalent Pharma Solutions does allow up to 40 hours of carryover of unused PTO each calendar year.

Start Date: Your first day of employment will be on September 19, 2022, subject to the satisfactory completion of a background check and drug screening test.

Severance: You will receive a separate severance letter agreement, which entitles you to a severance benefit equal to your annual base salary plus MIP target bonus, subject to the terms of the letter agreement.

Stock Ownership: As Vice President and Chief Accounting Officer, you will not be subject to stock ownership requirements.

Reimbursement of legal fees: Within 60 days of your hire date, Catalent will reimburse you for legal fees you may have incurred in conjunction with the acceptance of this offer up to $2,000.

Financial Planning: Each calendar year, as a member of the ELT, you are eligible for financial planning either by using AYCO (Goldman Sachs Company) or a financial planner of your choice. If you use a financial planner of your choice, your maximum reimbursement per annum is $15,000 which will be considered taxable income and taxed accordingly. More details on financial planning will be provided after your hire date.

Offer Requirements: Consistent with our policies for all Catalent personnel and the special considerations of our industry, this offer is contingent upon the satisfactory completion of a drug screen and background check, including reference checks.

The company-paid drug screen must be completed within 30 calendar days prior to your start date, with acceptable results. After acceptance of this offer, a chain of custody form, required for your drug screen, will be sent to you via e-mail by our vendor with information on how to complete the drug screen. The e-mail will also contain contact information for the nearest testing facility to your home address. Be sure to bring a printed copy of the e-mail along with a government-issued photo ID to the facility in order to process your drug screen.

A background check, including reference checks, must be complete prior to your start of employment, with satisfactory results. You will be receiving an e-mail from our vendor with information on how to complete the necessary documentation to initiate the required checks and to provide your authorization.

On your first day of employment, you will receive and will be asked to sign the Catalent Pharma Solutions Confidentiality Agreement.

The Immigration Reform and Control Act of 1986 requires employers to verify the employment eligibility and identity of all new employees. In accordance with this Act, please bring the appropriate identifying documents with you on your first day of employment. An electronic copy of the I-9 form including a list of accepted documentation of proof of work authorization will be sent to you after you pass all pre-hire contingencies.

Catalent does not hire employees for the purpose of acquiring their former employers’ trade secrets, intellectual property, or other confidential or proprietary information. In that regard, Catalent expects you to



honor your legal obligations to your former employer(s), and you are not permitted to utilize any confidential or proprietary information of your former employer(s) in order to conduct business on behalf of Catalent under any circumstances.

Your signature accepting this offer of employment is also your confirmation that you are either not a party to a non-competition or non-solicitation agreement that implicates your duties at Catalent or are a party to such an agreement and will honor your legal obligations to your current (and/or former) employer. If you believe that you cannot perform effectively for Catalent under any lawful and applicable restriction, you must inform Catalent of that fact. Further, in the event any legal action is taken by your former employer as a result of your employment by Catalent, Catalent will have no legal obligation to be responsible for your legal fees, representation, or damages associated with that legal action. Catalent will take whatever steps it deems appropriate under those circumstances.

Term: Employment with Catalent is not for any definite period of time and is terminable, with or without notice or reason, at the will of either you or the company. There shall be no contract of employment, express or implied.

Ethics: As a company founded on a core set of values, you will be provided with Catalent’s Standards of Business Conduct and will be required to sign a letter of compliance.

Please signify your acceptance of this offer of employment by scanning/emailing a signed/dated copy of this offer letter to my attention.

If you have any questions, please feel free to call me at XXX-XXX-XXXX.

Sincerely,

/s/ Ricardo Pravda

Ricardo Pravda

I accept the above offer of employment:

/s/ Karen Santiago 31-Aug-2022
Karen Santiago Date



imageb.jpg

14 Schoolhouse Road
Somerset NJ 08873 USA
catalent.com

+ 1 888 SOLUTION (76588466)

Press Release

Contacts:
MediaInvestor Relations
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Paul Surdez
+1 (732) 537 6325
investors@catalent.com

Catalent Appoints Karen Santiago as Vice President and Chief Accounting Officer

SOMERSET, N.J. – September 19, 2022 – Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the appointment of Karen Santiago as Vice President and Chief Accounting Officer. Karen will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.

Prior to joining Catalent, Karen spent 19 years with Bristol-Myers Squibb in various roles of increasing responsibility, including Senior Vice President & Corporate Controller, Principal Accounting Officer from 2018 to 2022, and Lead Enabling Functions and Finance Transformation from 2016 to 2018. Since 2013, she has served on the board of The Arc of New Jersey, the state's largest organization advocating for and serving children and adults with intellectual and developmental disabilities and their families. She holds a Masters in Business Administration and a Bachelor of Science in Accounting from Rutgers University.

“I am delighted to welcome Karen to lead our accounting function,” commented Thomas Castellano, Senior Vice President and Chief Financial Officer. “Her extensive background and deep finance expertise make her a valued addition to the team.”

Notes for Editors

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 19,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™